AQR Flex 1 Series LLC - Series D17 has filed a new offering under SEC Regulation D, marking a notable step in its investment strategy. The filing, submitted on October 29, 2026, indicates the company's intent to attract significant capital through pooled investment funds, particularly in the hedge fund sector.
The filing reveals that the company has set a minimum investment threshold of $15 million, which could appeal to high-net-worth individuals and institutional investors. This strategic move may enhance the firm's ability to raise capital and expand its investment portfolio.
Background
AQR Flex 1 Series LLC - Series D17 is a limited liability company incorporated in Delaware. It operates within the pooled investment fund industry, specifically focusing on hedge fund investments. The company is based in Greenwich, Connecticut, at One Greenwich Plaza, Suite 130. AQR Capital Management II, LLC serves as the promoter, while AQR Capital Management, LLC acts as the investment manager.
What the Filing Says
The SEC filing states, "Rule 506(b) provides a 'safer harbor' for a private offering." It also confirms that the investment company is not subject to the Investment Company Act Section 3(c) and Section 3(c)(7). The filing indicates that the offering is not an amendment and includes a total amount sold of $15 million.
Impact
This new offering may significantly impact potential investors, particularly those looking for hedge fund opportunities. With a minimum investment requirement set at $15 million, the company is targeting a specific investor demographic, which could influence competition within the hedge fund space.
What's Next
The filing does not say what happens next.
Read Next
Workers United Files to Sell $8.4 Million in Amalgamated Stock
Carvana Co. files to sell 10 million shares of stock
Platford Giles Richard to Sell 55,617 Takeda Shares
Takeda's Teresa Bitetti to Sell 46,609 Shares Amid Tax Obligations
Kiniksa Pharmaceuticals reports significant stock sale by officer
Moat Ross to Sell Over 103,000 Shares of Kiniksa Pharmaceuticals










